Article Text

Download PDFPDF
Expressions of Estrogen and Progesterone Receptors in Epithelial Ovarian Cancer: A Clinicopathologic Study
  1. Siriwan Tangjitgamol, MD*,,
  2. Sumonmal Manusirivithaya, MD*,
  3. Jakkapan Khunnarong, MD*,
  4. Somneuk Jesadapatarakul, MD and
  5. Sujitra Tanwanich, MSc
  1. *Departments of Obstetrics and Gynecology, and
  2. Departments of Anatomical Pathology, Bangkok Metropolitan Administration Medical College and Vajira Hospital, Dusit, Bangkok, Thailand.
  1. Address correspondence and reprint requests to Siriwan Tangjitgamol, MD, Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Bangkok Metropolitan Administration Medical College and Vajira, Hospital, 681 Samsen, Dusit, Bangkok 10300, Thailand. E-mail: siriwanonco{at}


Although estrogen (ER) and progesterone (PR) receptors are well recognized as important prognostic indicators of breast and endometrial cancers, their clinical significance in epithelial ovarian cancer is not clear with the limited data from only few immunohistochemical studies. The aim of this study was to evaluate the expressions of ER and PR in patients with epithelial ovarian cancer who were treated in our institution during the period 1996 to 2003. Their associations with clinicopathologic factors of age, stage, histologic subtypes, and grade and their prognostic role to survivals were also examined. Among 106 subjects included in the study, ER and PR expressions were found in 39.6% and 33.0%, respectively, with the corresponding highest expression in serous and endometrioid carcinomas. Estrogen receptor expression had a significant association with age older than 60 years, non-clear cell carcinomas, and high-grade tumors, whereas PR expression showed a significant association with non-clear cell carcinomas and a better response to first-line chemotherapy. Progesterone receptor expression was a favorable prognostic factor to both progression-free and overall survivals from univariable but not multivariable analyses. Expression of ER or any combination of ER/PR subgroups did not have a significant impact on survivals.

  • Estrogen receptor
  • Progesterone receptor
  • Epithelial ovarian cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.